Search
Levacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT inte...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEncainide
go.drugbank.com/drugs/DB01228ApprovedWithdrawnAll drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent hea...
Synonyms: (±)-2'-[2-(1-methyl-2-piperidyl)ethyl]-p-anisanilideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesChlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Categories: P-glycoprotein inhibitorsGemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigationalGemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet,...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnA long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activi...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalSunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant g...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesArformoterol
go.drugbank.com/drugs/DB01274ApprovedArformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic br...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesHydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigationalOriginally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hyperte...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsGlisoxepide
go.drugbank.com/drugs/DB01289InvestigationalGlisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes. However it inhibits taurocholate uptake only in the absence of sodium ions. Glisoxepide uptake co...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates